Prostate cancer (CaP) is the second leading cause of cancer-related deaths in western men.
Because androgens drive CaP by activating the androgen receptor (AR), blocking AR's …

Since prostate cancer (PCa) was described as androgen-dependent, the androgen receptor
(AR) has become the mainstay of its systemic treatment: androgen deprivation therapy …

Crosstalk between the androgen receptor (AR) and other signaling pathways in prostate
cancer (PCa) severely affects the therapeutic outcome of hormonal therapy. Although anti …

The standard treatment for prostate cancer (PCa) is androgen deprivation therapy (ADT) that
blocks transcriptional activity of androgen receptor (AR). However, ADT invariably leads to …

Patients diagnosed with localized high-risk prostate cancer have uncertain outcomes, and
the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult …

Background Resistance to androgen deprivation therapies is a major driver of mortality in
advanced prostate cancer. Therefore, there is a need to develop new preclinical models that …

Background Molecular characterization of tumors could be a key to therapeutic decision-
making with regards to targeted therapies in castration-resistant prostate cancer (CRPC). A …

The histopathology slide seminar “Classic Examples in Toxicologic Pathology XXVII” was
held on February 21 and 22, 2020, at the Department of Pathology at the University of …

Cancer is one of the leading causes of death for people worldwide. Since the completion of
the Human Genome Project, Next-Generation Sequencing has made leaps in …

Recent advances in androgen deprivation therapies for prostate cancer (PCa) have
improved patient outcomes. In addition, metastatic biopsies enable a better molecular …